Inmune Bio, Inc.
INmune Bio (Nasdaq: INMB) is a clinical-stage biotechnology company developing therapies intended to reprogram the innate immune system for diseases associated with chronic inflammation and immune dysfunction. Its lead program, CORDStrom, is an off-the-shelf, pooled human umbilical cord-derived mesenchymal stromal… From the company’s description.
Over the twelve months to Sep 30, 2026, Inmune Bio, Inc. reported a net loss of $16.67M. Operations used $12.91M in cash. In fiscal 2025, it reported revenue of $0.05M, up 257.1% from fiscal 2024, and a net loss of $45.93M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Inmune Bio, Inc. does
In the company’s own words
INmune Bio (Nasdaq: INMB) is a clinical-stage biotechnology company developing therapies intended to reprogram the innate immune system for diseases associated with chronic inflammation and immune dysfunction. Its lead program, CORDStrom, is an off-the-shelf, pooled human umbilical cord-derived mesenchymal stromal cell platform being developed for recessive dystrophic epidermolysis bullosa, a rare inherited disease. The company also develops XPro1595, a protein therapeutic designed to selectively neutralize soluble tumor necrosis factor and address neuroinflammation, with Alzheimer’s disease as its primary focus. Its oncology program, INKmune, is designed to prime patients’ natural killer cells to attack cancer cells and has been studied in metastatic castrate-resistant prostate cancer. The company operates through a single biotechnology business focused on these three product platforms rather than separately reported revenue segments. In 2025, CORDStrom completed a pivotal randomized crossover trial, while the XPro Phase II Alzheimer’s trial and the INKmune prostate cancer Phase I/II trial had also been completed. The company’s product candidates remain in clinical development.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOCA RATON, FL
- Fiscal year end
- December
- CIK
- 1711754
- SIC
- 2836
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Inmune Bio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Inmune Bio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Inmune Bio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Inmune Bio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Inmune Bio, Inc.'s last four quarterly filings that the numbers alone won't show?”